For example, the PD-1+CD8+/PD-1+Treg ratio in tumor-resident cells was reported to predict the clinical efficacy of PD-1 ICB (45), and a combinatorial analysis of LAG-3 expression on several peripheral blood cell subsets (prominently on CD8+ T cells) before the start of PD-1 ICB correlated with poorer clinical outcome (46). This evidence concerns the gene CD8A and neoplasm.